Payment overview · 2025
General Payments
$38.83
2 reported records · 2 companies
Healthcare provider profile · identity verified
Michael S Higginbotham, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROCKPORT, AR · NPI 1619992377
Verified facts
What the public records show
CMS Open Payments records show Michael S Higginbotham, MD received $38.83 in general payments during 2025 across 2 reported records.
Abbott Laboratories accounted for 59.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.92 | 59.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.91 | 41.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $38.83 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 621 | 189 |
| Tramadol Hcl | Tramadol Hcl | 542 | 99 |
| Losartan Potassium | Losartan Potassium | 501 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 430 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 107 |
| Gabapentin | Gabapentin | 320 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 106 |
| Lisinopril | Lisinopril | 308 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 306 | 96 |
| Omeprazole | Omeprazole | 305 | 88 |
| Pregabalin | Pregabalin | 304 | 59 |
| Simvastatin | Simvastatin | 301 | 92 |
| Metoprolol Tartrate | Metoprolol Tartrate | 281 | 86 |
| Meloxicam | Meloxicam | 269 | 89 |
| Famotidine | Famotidine | 246 | 87 |
| Furosemide | Furosemide | 235 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 66 |
| Eliquis | Apixaban | 212 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 196 | 33 |
| Potassium Chloride | Potassium Chloride | 195 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 72 |
| Metformin Hcl Er | Metformin Hcl | 180 | 54 |
| Carvedilol | Carvedilol | 173 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 55 |
| Metformin Hcl | Metformin Hcl | 172 | 55 |
| Clonazepam | Clonazepam | 162 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 38 |
| Glipizide | Glipizide | 149 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 145 | 54 |
| Ozempic | Semaglutide | 135 | 31 |
| Trazodone Hcl | Trazodone Hcl | 134 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 43 |
| Jardiance | Empagliflozin | 131 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 35 |
| Warfarin Sodium | Warfarin Sodium | 124 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 35 |
| Prednisone | Prednisone | 112 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 30 |
| Alprazolam | Alprazolam | 95 | 17 |
| Sertraline Hcl | Sertraline Hcl | 92 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 33 |
| Allopurinol | Allopurinol | 86 | 29 |
| Montelukast Sodium | Montelukast Sodium | 85 | 31 |
| Buspirone Hcl | Buspirone Hcl | 77 | 26 |
| Topiramate | Topiramate | 77 | 20 |
| Lorazepam | Lorazepam | 74 | 11 |
| Celecoxib | Celecoxib | 70 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 19 |
| Donepezil Hcl | Donepezil Hcl | 66 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 16 |
| Spironolactone | Spironolactone | 58 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 29 |
| Atenolol | Atenolol | 55 | 16 |
| Baclofen | Baclofen | 55 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 18 |
| Cephalexin | Cephalexin | 52 | 46 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 52 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 18 |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 15 |
| Sucralfate | Sucralfate | 49 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 20 |
| Ondansetron Odt | Ondansetron | 46 | 33 |
| Clonidine Hcl | Clonidine Hcl | 45 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 15 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 40 |
| Farxiga | Dapagliflozin Propanediol | 42 | 14 |
| Fluconazole | Fluconazole | 42 | 28 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Linzess | Linaclotide | 36 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Finasteride | Finasteride | 34 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 13 |
| Nitroglycerin | Nitroglycerin | 33 | 22 |
| Azithromycin | Azithromycin | 32 | 28 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 19 |
| Lovastatin | Lovastatin | 30 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | 12 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 18 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Dofetilide | Dofetilide | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $38.83 · 2 records | Abbott Laboratories | BREZTRI, CARDIOMEMS | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error